Working Groups

Latest News

May issue of IJAA

Read the latest issue and Editor's Choice articles

Read More
New position paper

Antimicrobial therapeutic guidelines from leading experts including ISAC's ICU & Sepsis Working ...

Read More


Current Officers


Jian Li


Gauri G. Rao


Zackery P. Bulman


Jaime Lora-Tamayo

All Members

Christian Eckmann (Germany)
Evangelos J. Giamarellos-Bourboulis (Greece)
Ian Gould (UK)
Teresita Mazzei (Italy)
Andrea Novelli (Italy)
Federico Pea (Italy)
Gianpaolo Perletti (Italy)
Francesco Scaglione (Italy)
Kazuhiro Tateda (Japan)
Ursula Theuretzbacher (Austria)
Paul M. Tulkens (Belgium)
Florian Wagenlehner (Austria)
Minggui Wang (China)


How to Join

Members of an ISAC Member Society are eligible to join any of our Working Groups. If you are a member and would like to join this group, please contact Fee Johnstone, ISAC Executive Assistant at

Aims and Objectives

Over the last 20 years, we assisted in an emerging crisis of antibiotic resistance for microbial pathogens throughout the world, at the very moment when increasing antimicrobial resistance has created the development of new antibiotics with novel mechanisms of action lacking. In this era the optimal use of old and eventually new antimicrobials became mandatory. The appropriate use of antimicrobials based on their pharmacological properties, including pharmacokinetic/pharmacodynamics (PK/PD) relationship, is one way to achieve clinical success. By using pharmacological information researchers, regulators and clinicians can achieve the goal of maximal therapeutic effect while reducing the risks of drug exposure-related adverse events as well as the selection of resistance. While this is now more and more recognized by Academia, Industry and Regulatory Agencies, there is presently a lack of training into these disciplines. The same applies to other areas of development of anti-infectives such as antiviral, antifungal and antiprotozoal. 

This Working Group aims to promote international exchange of ideas and new research into all aspects of anti-infective pharmacology, also in collaboration with other scientific societies.

The Work Plan for the group is as follows: 

  • Organise a workshop on anti-infective pharmacology during the biannual ISAC Congress
  • Organise occasional educational meetings
  • Encourage scientific exchange with other scientific organizations
  • Implement the PK/PD approach in anticancer chemotherapy
  • Apply for research grants


27-30 June 2015 Summer School on Anti-Infective Pharmacology, Italy
6-9 June 2013 Symposium for the 28th ICC in Yokohama, Japan
8-11 Nov 2012 Symposium at the 3rd SEEC in Dubrovnik, Croatia
November 2011 Symposium at the 2nd SEEC in Belgrade, Serbia
7-10 May 2011 Symposium at the 21st ECCMID/17th ICC in Milan, Italy with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG) and the ISC Working Group: Antimicrobials of the Future
September 2010 Summer School on Anti-Infective Pharmacology, Palazzo Feltrinelli, Gargnano, Italy


Projects / Publications

Associate Partner in the project DRIVE-AB (Driving Reinvestment in R&D and Responsible Antibiotic Use). DRIVE-AB is a public-private consortium funded by the EU Innovative Medicines Initiative (IMI) and part of the New Drugs for Bad Bugs (ND4BB) programme. Drive Website


Last updated: January 20th-2020